Cellular immune response – Page 14 – Communicable Diseases Research

COVID-19 in Elderly, Immunocompromised or Diabetic Patients-From Immune Monitoring to Clinical Management in the Hospital

고령자, 면역저하, 당뇨병 환자의 코로나19-면역 모니터링부터 병원 내 임상 관리까지

Article

Published on 2022-04-012022-09-11
Journal: Viruses [Category] COVID19(2023년), SARS, 치료기술,

Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

면역 저하된 신장 동종이식 환자에서 SARS CoV-2 백신(BNT162b2)에 대한 체액 및 세포 면역 반응 평가

Article

Published on 2022-04-012022-09-11
Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] absence Allograft Assessing assessment belatacept BNT162b2 booster vaccinations both groups CD4+ CD8+ T-cell Cellular immune response controls Critical cytomegalovirus deficiencies demonstrated dose Efficacy examined healthy controls humoral IgG IgG response IgG responses immune immune response immune responses Immunocompromised immunosuppressive in both group individual Infection ISP kidney kidney transplant limit memory MMF mycophenolate mycophenolate mofetil no differences of BNT162b2 partial immunity Patient patients peptide peptides Pfizer Prednisone preventing infection protective immunity protocol recipient renal response responses SARS CoV-2 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines severe deficiency severity shown spike spike IgG T-cell T-cell immunity T-cell Response T-cell responses tacrolimus vaccination Vaccine
[DOI] 10.1111/tid.13813 PMC 바로가기 [Article Type] Article

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients

항CD20 치료 다발성 경화증 환자에서 1차부터 3차까지의 SARS-CoV-2 mRNA 백신 접종에서 체액성 면역 반응이 지속적으로 감소하고 세포 면역 반응이 지속됨

Article

Published on 2022-04-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단,

[키워드] Abbott Abbott Laboratories administration All participant All participants allowance anti-CD20 anti-CD20 therapy Antibody Response B cell BNT162b2 BNT162b2 mRNA Booster vaccine CD20 CD4 CD8 Cellular immune response cellular response Cohort dropped frequencies Frequency humoral include longitudinal study median monoclonal antibodies mRNA vaccination mRNA vaccine Multiple multiple sclerosis no difference Ocrelizumab participant Patient PBMC peptide peptide pool Prophylactic reactive reduced reduction SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG II Quant assay SARS-CoV-2 vaccination second vaccination seropositive Seropositivity Spike-specific T-cell responses Study design sustained T-cell T-cell Response T-cell responses T-cells T-lymphocyte treated vaccination was done were assessed were measured
[DOI] 10.1016/j.msard.2022.103729 PMC 바로가기 [Article Type] Article

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

인도 델타(B.1.617.2) 변이형 급증 시 SARS-CoV-2 감염에 대한 ChAdOx1 nCoV-19 백신의 효과: 테스트 음성, 사례 대조군 연구 및 백신 접종 후 면역 반응에 대한 기계론적 연구

Article

Published on 2022-04-012022-09-11
Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 치료법,

[키워드] 95% CI addition adjusted Alpha antibody Antigen B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta Biotechnology case-control study CD4 CD8 T-cell response CD8 T-cell responses cellular Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Complete conserved Control Council COVID-19 COVID-19 vaccine delta variant Department disease effective Effectiveness geometric mean geometric mean titre healthy Humoral immunity immune protection immune response immune responses In-vitro India individual Industrial infected individuals laboratory-confirmed SARS-CoV-2 infection Mild Mild disease moderate-to-severe COVID-19 negative RT-PCR neutralisation neutralising antibody neutralising antibody response Neutralising antibody responses participant PCR test positive RT-PCR Primary outcome recipient remained Research RT-PCR test SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants secondary outcome Secondary outcomes single dose Spike protein Spike-specific T-cell responses T-cell immune response T-cell immune responses T-cell Response tested the spike protein vaccinated individuals vaccination Vaccine variant variant of SARS-CoV-2 variants VoC VOCs wild-type SARS-CoV-2 with mild disease
[DOI] 10.1016/S1473-3099(21)00680-0 PMC 바로가기 [Article Type] Article

SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease

자가면역 간염 및 자가면역 담즙정체성 간질환 환자에서 SARS-CoV-2 예방접종 반응

Observational Study

Published on 2022-04-012022-09-11
Journal: United European gastroenterology journal [Category] COVID19(2023년), SARS, 임상, 치료기술,

[키워드] absence antibody antibody levels Antibody Response Antibody responses Antibody titer Antibody titers Autoimmune Autoimmune hepatitis booster Cellular immune response chronic liver disease Cohort contributed Control COVID-19 vaccination declined demonstrated DiaSorin healthy control humoral immunization immunoassay Immunosuppression individuals LIAISON liver Liver disease marker observational study Patient patients positive serology primary biliary cholangitis primary sclerosing cholangitis PSC responders Roche SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine sclerosing cholangitis second vaccination Seroconversion significantly Specific T-cell response spike-specific T-cell response subset T-cell Response undetectable vaccination
[DOI] 10.1002/ueg2.12218 PMC 바로가기 [Article Type] Observational Study

Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome

원발성 쇼그렌 증후군 환자에서 코로나19 예방접종의 면역원성과 안전성

Article

Published on 2022-04-012022-09-12
Journal: RMD Open [Category] COVID19(2023년), SARS, 진단,

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination

1273-mRNA SARS-CoV-2 백신 접종 후 장기 혈액투석 환자에서 강력한 세포 및 체액 면역 반응의 발달

Article

Published on 2022-03-232022-09-12
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단,

[키워드] acute respiratory syndrome Analysis BNT162b2 vaccine cellular Cellular immune response cellular immunity cellular response Chronic kidney disease coronavirus COVID-19 COVID-19 vaccination Critical determine develop development exhibited favor healthy volunteer Hemodialysis High-risk patients humoral humoral immune response Humoral response IL-2 immune immune response Immunocompromised immunocompromised condition Infection kidney mortality rate naïve Patient patients potent PROTECT protective effect protocol response robust SARS-CoV-2 SARS-CoV-2 vaccine secretion serological response significantly vaccination vaccination against COVID-19 vaccine dose
[DOI] 10.3389/fimmu.2022.845882 PMC 바로가기 [Article Type] Article

Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients

SARS-CoV-2 mRNA 예방접종 면역저하 환자의 체액 및 세포 반응 평가

Observational Study

Published on 2022-03-222022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] administration anti-SARS-CoV-2 antibodies antibody antigens BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine cellular Cellular immune response cellular response Chronic kidney disease CKD Cohort cohorts Complete condition control group correlated detectable DiaSorin evaluated group healthy control healthy controls homogeneous humoral Humoral and cellular immune responses Humoral response IgG immune disorder immune disorders immune response immune responses Immunocompromised Immunocompromised patient Immunocompromised patients immunodeficiency immunogenicity increased risk interferon gamma Kidney disease mRNA multiple sclerosis neurologic no significant difference no significant differences Patient patients PID PLWH Primary Immunodeficiency proportion proportions Prospective Study Qiagen QuantiFERON quantification reactive response Risk factors SARS-CoV-2 SARS-CoV-2 antigen second vaccination severe COVID-19 significantly spike subject systemic the healthy the patient therapy These data vaccination vaccine response variety were measured with HIV
[DOI] 10.3389/fimmu.2022.858399 PMC 바로가기 [Article Type] Observational Study

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

SARS-CoV-2 감염 및 백신 접종은 부스터 전략에 영향을 미치는 수명이 긴 B 및 CD4+ T 림프구를 유발합니다

Article

Published on 2022-03-152022-09-11
Journal: The Journal of Clinical Investigation [Category] MERS, SARS, 변종, 진단, 치료기술,

[키워드] Adaptive immunity anti-spike immunity antibody antibody levels booster booster dose booster injection breakthrough infections causative agent CD4+ T cell CD4+ T cells CD4+ T lymphocyte Cellular immune response cellular immunity clinical clinical medicine Cohort CoV COVID-19 COVID-19 infection decay Department detectable Florence funds humoral humoral and cellular immunity Humoral immunity immune response Immunological memory implication individual individuals infected individuals Infection injection Italian Longitudinal evaluation Medicine memory B memory cell Memory cells Ministry of Health mRNA vaccination naïve individuals natural infection neutralization capacity occur performed persistence PROTECT reduced Reinfection restored SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants SARS-CoV-2-infected individuals severe disease significantly Spike protein supported T cells Tuscany university vaccinated individual vaccinated individuals vaccination
[DOI] 10.1172/JCI157990 PMC 바로가기 [Article Type] Article

Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies

mRNA 백신 접종으로 유도된 오래 지속되는 세포 면역 반응: 예방 전략에 대한 시사점

Article

Published on 2022-03-102022-09-12
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단,